{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:38:58Z","timestamp":1772815138063,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,8,29]],"date-time":"2008-08-29T00:00:00Z","timestamp":1219968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00277-008-0588-3","type":"journal-article","created":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T07:06:18Z","timestamp":1219907178000},"page":"301-310","source":"Crossref","is-referenced-by-count":55,"title":["Deferasirox in MDS patients with transfusion-caused iron overload\u2014a phase-II study"],"prefix":"10.1007","volume":"88","author":[{"given":"Georgia","family":"Metzgeroth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Dinter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Dorn-Beineke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kira","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Leismann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Hastka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,29]]},"reference":[{"issue":"2","key":"588_CR1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2001.03195.x","volume":"115","author":"JB Porter","year":"2001","unstructured":"Porter JB (2001) Practical management of iron overload. Br J Haematol 115(2):239\u2013252","journal-title":"Br J Haematol"},{"issue":"3","key":"588_CR2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF02982791","volume":"76","author":"RS Britton","year":"2002","unstructured":"Britton RS, Leicester KL, Bacon BR (2002) Iron toxicity and chelation therapy. Int J Hematol 76(3):219\u2013228","journal-title":"Int J Hematol"},{"key":"588_CR3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/asheducation-2001.1.47","volume":"2001","author":"JP Kushner","year":"2001","unstructured":"Kushner JP, Porter JP, Olivieri NF (2001) Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001:47\u201361","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"588_CR4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/10408368309165764","volume":"19","author":"GD McLaren","year":"1983","unstructured":"McLaren GD, Muir WA, Kellermeyer RW (1983) Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci 19(3):205\u2013266","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"588_CR5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.1996.d01-1795.x","volume":"94","author":"PD Jensen","year":"1996","unstructured":"Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T et al (1996) The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 94(2):288\u2013299","journal-title":"Br J Haematol"},{"issue":"5","key":"588_CR6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0609.2004.00304.x","volume":"73","author":"A Aessopos","year":"2004","unstructured":"Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J et al (2004) Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 73(5):359\u2013366","journal-title":"Eur J Haematol"},{"issue":"25","key":"588_CR7","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM198506203122503","volume":"312","author":"L Wolfe","year":"1985","unstructured":"Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R et al (1985) Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 312(25):1600\u20131603","journal-title":"N Engl J Med"},{"issue":"9","key":"588_CR8","first-page":"788","volume":"83","author":"C Borgna-Pignatti","year":"1998","unstructured":"Borgna-Pignatti C, Franchini M, Gandini G, Vassanelli A, De Gironcoli M, Aprili G (1998) Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. Haematologica 83(9):788\u2013790","journal-title":"Haematologica"},{"issue":"1","key":"588_CR9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","volume":"118","author":"A Ceci","year":"2002","unstructured":"Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De S V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefano I, Tricta F (2002) The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 118(1):330\u2013336","journal-title":"Br J Haematol"},{"issue":"2","key":"588_CR10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2141.2000.01866.x","volume":"08","author":"AR Cohen","year":"2000","unstructured":"Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F (2000) Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 08(2):305\u2013312","journal-title":"Br J Haematol"},{"issue":"1","key":"588_CR11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2002-06-1867","volume":"102","author":"AV Hoffbrand","year":"2003","unstructured":"Hoffbrand AV, Cohen A, Hershko C (2003) Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102(1):17\u201324","journal-title":"Blood"},{"issue":"9","key":"588_CR12","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","volume":"107","author":"MD Cappellini","year":"2006","unstructured":"Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L et al (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107(9):3455\u20133462","journal-title":"Blood"},{"issue":"2","key":"588_CR13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.beha.2004.09.002","volume":"18","author":"MD Cappellini","year":"2005","unstructured":"Cappellini MD (2005) Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 18(2):289\u2013298","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"588_CR14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V97.4.1115","volume":"97","author":"C Hershko","year":"2001","unstructured":"Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G (2001) ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 97(4):1115\u20131122","journal-title":"Blood"},{"issue":"12","key":"588_CR15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2174\/0929867033457610","volume":"10","author":"H Nick","year":"2003","unstructured":"Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J et al (2003) Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 10(12):1065\u20131076","journal-title":"Curr Med Chem"},{"issue":"10","key":"588_CR16","first-page":"1343","volume":"91","author":"R Galanello","year":"2006","unstructured":"Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E et al (2006) Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 91(10):1343\u20131351","journal-title":"Haematologica"},{"issue":"6","key":"588_CR17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0091270003253350","volume":"43","author":"R Galanello","year":"2003","unstructured":"Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R (2003) Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 43(6):565\u2013572","journal-title":"J Clin Pharmacol"},{"issue":"9369","key":"588_CR18","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(03)13309-0","volume":"361","author":"E Nisbet-Brown","year":"2003","unstructured":"Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R et al (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361(9369):1597\u20131602","journal-title":"Lancet"},{"issue":"7","key":"588_CR19","first-page":"873","volume":"91","author":"A Piga","year":"2006","unstructured":"Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A et al (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91(7):873\u2013880","journal-title":"Haematologica"},{"issue":"2)(Suppl 3","key":"588_CR20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminhematol.2007.03.004","volume":"44","author":"J Porter","year":"2007","unstructured":"Porter J (2007) Clinical evaluation of deferasirox (Exjade((R)), ICL670). Semin Hematol 44(2):16\u201320","journal-title":"Semin Hematol"},{"issue":"10","key":"588_CR21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1358\/dot.2006.42.10.1009901","volume":"42","author":"JB Porter","year":"2006","unstructured":"Porter JB (2006) Deferasirox: an effective once-daily orally active iron chelator. Drugs Today (Barc) 42(10):623\u2013637","journal-title":"Drugs Today (Barc)"},{"issue":"Suppl 3","key":"588_CR22","first-page":"16","volume":"31","author":"SL Goldberg","year":"2007","unstructured":"Goldberg SL (2007) Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leuk Res 31(Suppl 3):16\u201322","journal-title":"Leuk Res"},{"key":"588_CR23","volume-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon"},{"issue":"9406","key":"588_CR24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0140-6736(04)15436-6","volume":"363","author":"Y Gandon","year":"2004","unstructured":"Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V et al (2004) Non-invasive assessment of hepatic iron stores by MRI. Lancet 363(9406):357\u2013362","journal-title":"Lancet"},{"issue":"4","key":"588_CR25","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2004-10-3982","volume":"106","author":"JC Wood","year":"2005","unstructured":"Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD et al (2005) MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 106(4):1460\u20131465","journal-title":"Blood"},{"issue":"2","key":"588_CR26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/jmri.20489","volume":"23","author":"E Alexopoulou","year":"2006","unstructured":"Alexopoulou E, Stripeli F, Baras P, Seimenis I, Kattamis A, Ladis V et al (2006) R2 relaxometry with MRI for the quantification of tissue iron overload in beta-thalassemic patients. J Magn Reson Imaging 23(2):163\u2013170","journal-title":"J Magn Reson Imaging"},{"issue":"9","key":"588_CR27","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","volume":"107","author":"DJ Pennell","year":"2006","unstructured":"Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A et al (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107(9):3738\u20133744","journal-title":"Blood"},{"issue":"4","key":"588_CR28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCULATIONAHA.104.504415","volume":"112","author":"JC Wood","year":"2005","unstructured":"Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD et al (2005) Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 112(4):535\u2013543","journal-title":"Circulation"},{"issue":"4","key":"588_CR29","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","volume":"115","author":"MA Tanner","year":"2007","unstructured":"Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A et al (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115(4):1876\u20131884","journal-title":"Circulation"},{"issue":"5","key":"588_CR30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10554-005-0651-2","volume":"21","author":"MA Westwood","year":"2005","unstructured":"Westwood MA, Firmin DN, Gildo M, Renzo G, Stathis G, Markissia K et al (2005) Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging 21(5):531\u2013538","journal-title":"Int J Cardiovasc Imaging"},{"issue":"2","key":"588_CR31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2571.x","volume":"77","author":"C Rose","year":"2006","unstructured":"Rose C, Vandevenne P, Bourgeois E, Cambier N, Ernst O (2006) Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients. Eur J Haematol 77(2):145\u2013149","journal-title":"Eur J Haematol"},{"issue":"1","key":"588_CR32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.6004\/jnccn.2006.0010","volume":"4","author":"PL Greenberg","year":"2006","unstructured":"Greenberg PL (2006) Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 4(1):91\u201396","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"588_CR33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2006.06455.x","volume":"136","author":"E Vichinsky","year":"2007","unstructured":"Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P et al (2007) A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136(3):501\u2013508","journal-title":"Br J Haematol"},{"issue":"3","key":"588_CR34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-0609.2005.00474.x","volume":"75","author":"SI Mavrogeni","year":"2005","unstructured":"Mavrogeni SI, Markussis V, Kaklamanis L, Tsiapras D, Paraskevaidis I, Karavolias G et al (2005) A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol 75(3):241\u2013247","journal-title":"Eur J Haematol"},{"issue":"11","key":"588_CR35","first-page":"43","volume":"113","author":"D Pennell","year":"2006","unstructured":"Pennell D (2006) MRI and iron-overload cardiomyopathy in thalassaemia. Circulation 113(11):43\u201344","journal-title":"Circulation"},{"issue":"3","key":"588_CR36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/14740338.6.3.235","volume":"6","author":"GJ Kontoghiorghes","year":"2007","unstructured":"Kontoghiorghes GJ (2007) Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 6(3):235\u2013239","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"588_CR37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trsl.2006.05.005","volume":"148","author":"JC Wood","year":"2006","unstructured":"Wood JC, Otto-Duessel M, Gonzalez I, Aguilar MI, Shimada H, Nick H et al (2006) Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 148(5):272\u2013280","journal-title":"Transl Res"},{"issue":"9488","key":"588_CR38","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0140-6736(05)67205-4","volume":"366","author":"GJ Kontoghiorghes","year":"2005","unstructured":"Kontoghiorghes GJ (2005) Effects of ICL670 (deferasirox) on cardiac iron concentrations. Lancet 366(9488):804","journal-title":"Lancet"},{"issue":"4","key":"588_CR39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2141.2007.06666.x","volume":"138","author":"A Maggio","year":"2007","unstructured":"Maggio A (2007) Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 138(4):407\u2013421","journal-title":"Br J Haematol"},{"key":"588_CR40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0609.2007.00985.x","volume":"80","author":"J Porter","year":"2007","unstructured":"Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD et al (2007) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80:168\u2013176, PMID 18028431","journal-title":"Eur J Haematol"},{"issue":"2","key":"588_CR41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1054\/blre.2002.0193","volume":"16","author":"G Weiss","year":"2002","unstructured":"Weiss G (2002) Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 16(2):87\u201396","journal-title":"Blood Rev"},{"issue":"1","key":"588_CR42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0145-2126(97)00089-1","volume":"22","author":"C Aul","year":"1998","unstructured":"Aul C, Germing U, Gattermann N, Minning H (1998) Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res 22(1):93\u2013100","journal-title":"Leuk Res"},{"issue":"3","key":"588_CR43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000052832","volume":"48","author":"H Burkhardt","year":"2002","unstructured":"Burkhardt H, Bojarsky G, Gretz N, Gladisch R (2002) Creatinine clearance, Cockcroft-Gault formula and cystatin C: estimators of true glomerular filtration rate in the elderly? Gerontology 48(3):140\u2013146","journal-title":"Gerontology"},{"issue":"783","key":"588_CR44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/pgmj.67.783.42","volume":"67","author":"DG Waller","year":"1991","unstructured":"Waller DG, Fleming JS, Ramsey B, Gray J (1991) The accuracy of creatinine clearance with and without urine collection as a measure of glomerular filtration rate. Postgrad Med J 67(783):42\u201346","journal-title":"Postgrad Med J"},{"issue":"1","key":"588_CR45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/ajkd.1998.v32.pm9669420","volume":"32","author":"M Walser","year":"1998","unstructured":"Walser M (1998) Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 32(1):23\u201331","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"588_CR46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4065\/81.2.197","volume":"81","author":"A Tefferi","year":"2006","unstructured":"Tefferi A (2006) Iron chelation therapy for myelodysplastic syndrome: if and when. Mayo Clin Proc 81(2):197\u2013198","journal-title":"Mayo Clin Proc"},{"key":"588_CR47","unstructured":"Abstracts of the 8th International Symposium on Myelodysplastic Syndromes. Nagasaki, Japan (2005) Leuk Res 29(1):1\u201378"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0588-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-008-0588-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0588-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T14:15:33Z","timestamp":1709216133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-008-0588-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,29]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1007\/s00277-008-0588-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,29]]}}}